GILZ: a new link between the hypothalamic pituitary adrenal axis and rheumatoid arthritis?. Issue 9 (22nd July 2014)

• Record Type: Journal Article
• Authors: Eades, Laura E; Thiagarajah, Angeline S; Harris, James; Jones, Sarah A; Morand, Eric F; Leech, Michelle
• Is Part Of: Immunology and cell biology. Volume 92:Issue 9(2014)
• Page Start: 747
• Page End: 751
• Publication Date: 2014-07-22
• Subjects: Immunology -- Periodicals; Cytology -- Periodicals; 616.079
• DOI: 10.1038/icb.2014.56
• Languages: English
• ISSNs: 0818-9641

Abstract

Abstract : The hypothalamic–pituitary–adrenal (HPA) axis is an important regulator of the stress response. In healthy individuals, the HPA axis maintains an equilibrium, ensuring that endogenous glucocorticoid (GC) levels remain within the normal range. However, hypofunction of the HPA axis may have a role in the development of inflammatory diseases, such as rheumatoid arthritis (RA). Glucocorticoid‐induced leucine zipper (GILZ) is an anti‐inflammatory protein, the expression of which is upregulated by GC. Although GILZ mediates the anti‐inflammatory effects of GC, it may not be associated with the adverse effects that are frequently caused by exogenous GC administration. This has raised interest in GILZ potentiation as a therapeutic approach in diseases such as RA, which may mimic the anti‐inflammatory effects of GC without causing harmful side effects. This review will outline the involvement of the HPA axis in RA, as a prelude to highlighting emerging evidence regarding the role of GILZ in inflammation control and RA.